Top Stories
- Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
- Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
- Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
- Bristol Myers' stock decline in response to weak guidance is a gift to investors
- China says will protect its own interests in face of U.S. 'bullying'